DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
Status:
Completed
Trial end date:
2019-01-03
Target enrollment:
Participant gender:
Summary
This three-part study will be performed with participants on chronic hemodialysis.
- Part A will assess plasma pharmacokinetics of DS2330a (free form of DS2330b) after a
single dose of powder in bottle (PIB) or tablet formulations of DS2330b
- Part B will test the safety, tolerability, and effects on serum phosphate (Pi) of 14-day
repeated oral doses of DS-2330b PIB when given alone and when given along with sevelamer
carbonate three times a day
- Part C is optional, and will test the effects on serum phosphate (Pi) of 14-day repeated
oral doses of DS-2330b tablets when given with sevelamer carbonate
After screening, participants should expect the study to last about 21 days for Part A, and
46 days for Parts B and C.